207_Combined course Presentations

Toxicity of concurrent SRT and BRAF-inhibitors

vemurafenib, dabrafenib

 Conflicting data on CNS toxicity after cranial SRT and BRAF-inhibitors

 High rates of toxicity warrant caution.

 No data on BRAF inhibitors and extra-cranial SRT.

Kroeze S et al. Cancer Treatment Reviews 53 (2017) 25–37